PMID- 23845043
OWN - NLM
STAT- MEDLINE
DCOM- 20131028
LR  - 20211021
IS  - 1471-2377 (Electronic)
IS  - 1471-2377 (Linking)
VI  - 13
DP  - 2013 Jul 11
TI  - Adverse events during the titration phase of interferon-beta in 
      remitting-relapsing multiple sclerosis are not predicted by body mass index nor 
      by pharmacodynamic biomarkers.
PG  - 82
LID - 10.1186/1471-2377-13-82 [doi]
AB  - BACKGROUND: This study aimed to correlate body mass index or biomarkers with the 
      frequency of common adverse events (AEs) with subcutaneous IFN beta-1a during 
      treatment titration in patients with relapsing-remitting multiple sclerosis 
      previously naive to IFN beta. METHODS: Eighty-four patients (66.3% females) were 
      followed up during 8 weeks, 25.3% were overweight and 14.5% were obese. RESULTS: 
      Biomarkers steadily increased during all study period by 45.3% for 
      beta2-microglobulin, 262.8% for olygoadenylate synthetase-1, and 92.8% for 
      neopterin. Overall AE reporting did not vary with the dose or treatment duration. 
      CONCLUSIONS: BMI was not predictive of increased risk for AEs. Biomarkers did not 
      discriminate on the frequency of any AE either.
FAU - Munoz, Delicias
AU  - Munoz D
AD  - Department of Neurology, Hospital Xeral-Cies, Pontevedra, Spain.
FAU - Escartin, Antonio
AU  - Escartin A
FAU - Dapena, Dolores
AU  - Dapena D
FAU - Coret, Francisco
AU  - Coret F
FAU - Fernandez-Uria, Dionisio
AU  - Fernandez-Uria D
FAU - Perez, Domingo
AU  - Perez D
FAU - Casanova, Bonaventura
AU  - Casanova B
FAU - Guijarro-Castro, Cristina
AU  - Guijarro-Castro C
FAU - Munteis, Elvira
AU  - Munteis E
FAU - del-Campo Amigo, Maria
AU  - del-Campo Amigo M
FAU - Pego, Robustiano
AU  - Pego R
FAU - Calles, Carmen
AU  - Calles C
FAU - Garcia-Rey, Cesar
AU  - Garcia-Rey C
FAU - Monsalve, Nuria
AU  - Monsalve N
FAU - Sanchez-Matienzo, David
AU  - Sanchez-Matienzo D
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20130711
PL  - England
TA  - BMC Neurol
JT  - BMC neurology
JID - 100968555
RN  - 0 (Immunologic Factors)
RN  - 0 (beta 2-Microglobulin)
RN  - 670-65-5 (Neopterin)
RN  - 77238-31-4 (Interferon-beta)
RN  - EC 2.7.7.- (OAS1 protein, human)
RN  - EC 2.7.7.84 (2',5'-Oligoadenylate Synthetase)
SB  - IM
MH  - 2',5'-Oligoadenylate Synthetase/metabolism
MH  - *Body Mass Index
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunologic Factors/*adverse effects
MH  - Interferon-beta/*adverse effects
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Multiple Sclerosis, Chronic Progressive/*drug therapy
MH  - Neopterin/metabolism
MH  - Predictive Value of Tests
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - beta 2-Microglobulin/metabolism
PMC - PMC3710468
EDAT- 2013/07/13 06:00
MHDA- 2013/10/29 06:00
PMCR- 2013/07/11
CRDT- 2013/07/13 06:00
PHST- 2013/02/12 00:00 [received]
PHST- 2013/07/10 00:00 [accepted]
PHST- 2013/07/13 06:00 [entrez]
PHST- 2013/07/13 06:00 [pubmed]
PHST- 2013/10/29 06:00 [medline]
PHST- 2013/07/11 00:00 [pmc-release]
AID - 1471-2377-13-82 [pii]
AID - 10.1186/1471-2377-13-82 [doi]
PST - epublish
SO  - BMC Neurol. 2013 Jul 11;13:82. doi: 10.1186/1471-2377-13-82.